Syneron Candela launches PicoWay Resolve™

Syneron Candela launched a new dual wavelength fractional modality for its PicoWay picosecond laser at the 24th European Academy of Dermatology and Venereology (EADV) Congress in Copenhagen – the PicoWay Resolve™. 

The new Resolve fractional picosecond modality, which features both 532nm and 1064nm wavelengths, comes less than a year after the November 2014 launch of the state-of-the-art PicoWay platform.

Resolve is the only picosecond device on the market to employ a holographic fractionator to deliver precisely consistent energy to the entire treatment area, which results in pristine, reproducible results.  Resolve's two wavelengths enable treatment of shallow lesions with the 532nm wavelength, while the 1064nm wavelength is used for deeper lesions and to treat all skin types, with no downtime.

"PicoWay continues to exceed expectations and delight customers. We are thrilled to introduce to the market the next step in the PicoWay story, Resolve, the fractional modality that uniquely includes two wavelengths. Our PicoWay customers know that we have a robust road map for PicoWay which includes expanded applications and new capabilities enabled by outstanding technology," said Amit Meridor, Chief Executive Officer of Syneron Candela. "It is energizing to witness the excitement that this product is experiencing in the marketplace as we introduce appealing new ways to utilize the technology to treat patients."

"We recently began to use the novel PicoWay fractional hand-pieces for skin rejuvenation, acne scars and wrinkles with improvement in skin tone, brightness and texture after one or two treatments," said David Friedman, MD, board certified dermatologist.